Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR

Clinical Cancer Research

Volumn 21, Issue 15, 2015, Pages 3552-3560

  Watanabe, Masaru ^a,b,c   Kawaguchi, Tomoya ^d,e   Isa, Shun Ichi ^d   Ando, Masahiko ^f   Tamiya, Akihiro ^d   Kubo, Akihito ^a,g   Saka, Hideo ^a   Takeo, Sadanori ^h   Adachi, Hirofumi ⁱ   Tagawa, Tsutomu ^j   Kakegawa, Seiichi ^h   Yamashita, Motohiro ^h   Kataoka, Kazuhiko ^k   Ichinose, Yukito ^l   Takeuchi, Yukiyasu ^m   Sakamoto, Kazuhiro ^h   Matsumura, Akihide ^d   Koh, Yasuhiro ^a,b,c  

^a NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^c SHIZUOKA CANCER CENTER   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^e OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f NAGOYA UNIVERSITY HOSPITAL   (Japan)

^g AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION   (Japan)

ⁱ HOKKAIDO CANCER CENTER   (Japan)

^j NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^k IWAKUNI NATIONAL HOSPITAL   (Japan)

^l NATIONAL KYUSHU CANCER CENTER   (Japan)

^m TONEYAMA NATIONAL HOSPITAL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GENOMIC DNA; METHIONINE; THREONINE; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER SURGERY; DNA FRAGMENTATION; DROPLET DIGITAL POLYMERASE CHAIN REACTION; EGFR GENE; FEMALE; GENE MUTATION; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NON SMALL CELL LUNG CANCER; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR VOLUME; WILD TYPE; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; GENE FREQUENCY; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; MUTATION; PATHOLOGY; PERSONALIZED MEDICINE; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE FREQUENCY; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PRECISION MEDICINE; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84942942154     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2151     Document Type: Article

References (40)

1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
2. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
3. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42.
4. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46.
5. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
6. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.
7. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. North-East Japan Study Group. Gefitinib or chemotherapy for non-smallcell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
8. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92.
9. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of mechanisms of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013;19:2240-7.
10. Ohashi K, Maruvka YE, Michor F, Pao W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol 2013;31:1070-80.
11. Inukai M, Toyooka S, Ito S, Asano H, Ichihara S, Soh J, et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small-cell lung cancer. Cancer Res 2006;66:7854-8.
12. Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, Yang PC. Effectiveness of tyrosine kinase inhibitors on 'uncommon' epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 2011;17:3812-21.
13. Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-9.
14. Li H, Hu H, Wang R, Pan Y, Wang L, Li Y, et al. Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients. Onco Targets Ther 2014;7:513-24.
15. Su KY, Chen HY, Li KC, Kuo ML, Yang JC, Chan WK, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with nonsmall-cell lung cancer. J Clin Oncol 2012;30:433-40.
16. Rosell R, Molina MA, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 2011;17:1160-8.
17. Fujita Y, Suda K, Kimura H, Matsumoto K, Arao T, Nagai T, et al. Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation. J Thorac Oncol 2012;7:1640-4.
18. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359:366-77.
19. Yu HA, Arcila ME, Hellmann MD, Kris MG, Ladanyi M, Riely GJ. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Ann Oncol 2014;25:423-8.
20. Costa C, Molina MA, Drozdowskyj A, Giménez-Capitán A, Bertran-Alamillo J, Karachaliou N, et al. The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin Cancer Res 2014;20:2001-10.
21. Ding D, Yu Y, Li Z, Niu X, Lu S. The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-smallcell lung cancer patients: a meta-analysis. Onco Targets Ther 2014;7:387-93.
22. Vogelstein B, Kinzler KW. Digital PCR. Proc Natl Acad Sci U S A 1999;96:9236-41.
23. Baker M. Digital PCR hits its stride. Nat Methods 2012;9:541-4.
24. Taly V, Pekin D, Abed AE, Laurent-Puig P. Detecting biomarkers with microdroplet technology. Trends Mol Med 2012;18:405-16.
25. Pekin D, Skhiri Y, Baret JC, Le Corre D, Mazutis L, Ben Salem C, et al. Quantitative and sensitive detection of rare mutations using droplet-based microfluidics. Lab Chip 2011;11:2156-66.
26. Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O'Connell A, Messineo MM, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 2014;20:1698-705.
27. Didelot A, Kotsopoulos SK, Lupo A, Pekin D, Li X, Atochin I, et al. Multiplex picoliter-droplet digital PCR for quantitative assessment of DNA integrity in clinical samples. Clin Chem 2013;59:815-23.
28. Taly V, Pekin D, Benhaim L, Kotsopoulos SK, Le Corre D, Li X, et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem 2013;59:1722-31.
29. Beaver JA, Jelovac D, Balukrishna S, Cochran RL, Croessmann S, Zabransky DJ, et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res 2014;20:2643-50.
30. Ono A, Kenmotsu H, Watanabe M, Serizawa M, Mori K, Imai H, et al. Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation. Ann Oncol 2014;25:1948-53.
31. Ito N, Kawaguchi T, Koh Y, Isa S, Shimizu S, Takeo S, et al. Driver mutations associated with smoking and other environmental factors: prospective and integrative genomic analysis from the Japan Molecular epidemiology for Lung Cancer Study (JME). J Clin Oncol 32:5s, 2014 (suppl; abstr 7516).
32. Yatabe Y, Hida T, Horio Y, Kosaka T, Takahashi T, Mitsudomi T. A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn 2006;8:335-41.
33. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67.
34. Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, Pao W. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 2011;17:5530-7.
35. Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, et al. Optimization of dosing for EGFRmutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 2011;3:90ra59.
36. Sequist LV, Soria JC, Gadgeel SM, Wakelee H, Camidge DR, Varga A, et al. Jonathan Goldman. First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). J Clin Oncol 32:5s, 2014 (suppl; abstr 8010).
37. Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR-TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014;4:1046-61.
38. Janne PA, Ramalingam SS, Yang JCH, Ahn MJ, Kim DW, Kim SW, et al. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC). J Clin Oncol 32:5s, 2014 (suppl; abstr 8009).
39. Yost SE, Smith EN, Schwab RB, Bao L, Jung H, Wang X, et al. Identification of high-confidence somatic mutations in whole genome sequence of formalin-fixed breast cancer specimens. Nucleic Acids Res 2012;40:e107.
40. Ye X, Zhu ZZ, Zhong L, Lu Y, Sun Y, Yin X, et al. High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact? J Thorac Oncol 2013;8:1118-20.